Clinical Trial Update: Transcriptional and Immune Parameters of Response to Belimumab

View source ↗

Summary

This completed study analyzes transcriptional and immune parameters associated with response to belimumab in systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Belimumab (belimumab)

Snippet

Sponsor: Biomedical Research Foundation, Academy of Athens | Conditions: Systemic Lupus Erythematosus | Status: COMPLETED